Intracameral triamcinolone acetonide as treatment for endothelial allograft rejection after penetrating keratoplasty.
OBJECTIVE
Intracameral injection of triamcinolone acetonide as treatment of therapy-resistant endothelial allograft rejection after penetrating keratoplasty is reported.


METHODS
A 32-year-old patient showed conventional therapy-resistant endothelial allograft rejection 2 months after penetrating keratoplasty. The patient received an intracameral injection of 4 mg in 0.1 mL of triamcinolone acetonide. Preinjection visual acuity was count fingers at 3 ft, and the graft showed diffuse haze and multiple endothelial rejection lines.


RESULTS
Within 2 weeks after injection, marked resolution of the microcystic edema and reversal of the endothelial rejection was noted. Fourteen months after injection, best-corrected visual acuity was 20/20, and intraocular pressure was 17 mm Hg without antiglaucoma therapy.


CONCLUSIONS
Intracameral injection of triamcinolone acetonide may be an additional treatment modality in the treatment of endothelial allograft rejection when traditional steroid therapies have failed.
Maris
Peter J G
PJ
Department of Ophthalmology, Nassau University Medical Center, East Meadow, NY, USA. pmaris@msn.com
Correnti
Anthony J
AJ
Donnenfeld
Eric D
ED
D000328:Adult; D000867:Anterior Chamber / Q000187:drug effects; D004728:Endothelium, Corneal / Q000473:pathology* / Q000637:transplantation; D005938:Glucocorticoids / Q000008:administration & dosage*; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D015948:Keratoplasty, Penetrating; D008297:Male; D014184:Transplantation, Homologous; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide